Vol. 1 Núm. 1 (2024): Sanitis
Artículos

TUBERCULOSIS LATENTE EN PACIENTES CON ARTRITIS REUMATOIDE TRATADOS CON ANTAGONISTAS DEL FACTOR DENECROSIS TUMORAL ALFA. HOSPITAL I.V.S.S DR. RAFAEL CALLES SIERRA, PUNTO FIJO, ESTADO FALCÓN.

PDF
  • Elaudi Rodríguez,
  • María Sampol
Portada Revista Sanitis de la Universidad Arturo Michelena
Categorías

Publicado 2024-05-31

Palabras clave

  • Artritis reumatoide,
  • tuberculosis latente,
  • antagonistas factor de necrosis tumoral alfa,
  • PPD,
  • Booster

Resumen

La incidencia de Tuberculosis en pacientes con artritis reumatoide es hasta 4 veces más alta cuando se compara con la población general, incrementándose el riesgo con el uso de drogas antagonistas factor de necrosis tumoral alfa (Anti FNT-α). En Venezuela no hay estudios publicados al respecto. El objetivo de este estudio fue estimar la prevalencia de tuberculosis latente en pacientes con artritis reumatoide tratados con antagonistas del Factor de Necrosis Tumoral alfa en la consulta de Reumatología del Hospital Dr. Rafael Calles Sierra, Punto Fijo, Estado Falcón. El estudio es de tipo descriptivo, ambispectivo, de corte transversal, exploratorio, no experimental, conformado por una muestra de 90 pacientes con diagnóstico de artritis reumatoide a quienes se le aplicó un instrumento, revisión de historia clínica y aplicación de PPD y Booster. El análisis estadístico se realizó con pruebas descriptivas e inferenciales, obteniéndose una prevalencia de 33,3% de tuberculosis latente; y factores de riesgo estadísticamente significativos, como edad, sexo, estrato social, hacinamiento, tiempo de diagnóstico de la enfermedad y del tratamiento e índice de actividad. En conclusión, las pruebas de PPD y Booster siguen siendo una herramienta de gran utilidad, menor costo y fácil aplicación en la detección de tuberculosis latente y la evaluación de los factores de riesgos para tuberculosis previo al uso de terapia biológica anti FNT disminuyen la prevalencia de esta patología.

PDF

Referencias

  1. Liu H. Case finding for population-based studies of rheumatoid arthritis: comparison of patient self-reported ACR criteria-based algorithms to physician-implicit review for diagnosis of rheumatoid arthritis. Sem Arthritis Rheum 2004; 33: 302-310.
  2. Singh J; Saag K; Bridges S; Akl E; Bannuru R; Sullivan M; et. Al. The American College of Rheumatology (ACR) last published a guideline for RA management in 2012. Arthritis Care & Research DOI 10.1002/acr.22783 VC 2015.
  3. Lipsky, (1994). Harrison principios de Medicina Interna, 16ª Edición, España: Interamericana Mc Graw-Hill.
  4. Braunwald, E. Harrison´s Principles of internal medicine. 15th Ed. Ciudad: Editorial Mc GrawHill interamericana 2001; 2.
  5. Smith J, Haynes M. Rheumatod Arthritis a molecular understanding. An Intern Med. 2002; 136: 908-922.
  6. Iain B. McInnes I, Schett. The Pathogenesis of Rheumatoid Arthritis. N Engl J Med 2011;365:2205-19.
  7. Rodríguez V; Cáliz R; Gracia A; Marenco JL; Mulero J; Tornero J; et al. III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide. Reumatol Clin. 2006; 2 (Supl 2): S52-S59.
  8. Belmonte M. ¿Es la puntuación DAS28 el método más adecuado para estimar la actividad de la artritis reumatoide? Consideraciones clinimétricas y escenarios de simulación. Reumatol Clin. 2008;4(5):18390
  9. Gardam M; Keystone E; Menzies R; Manners S; Skamene E; Long R; et. al. Antitumor necrosis factor agents and tuberculosis risk: mechanisms of action and management. Lancet Infect Dis. 2003; 3:148-55.
  10. Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S. MonitorNet: he Italian multicentre observational study aimed a estimating the risk/benefit profile of biologic agents in realworld rheumatology practice. Reumatismo, 2009; 61 (2): 132-139.
  11. Kuriya B; Arkema EV; Bykerk VP; Keystone EC. Efficacy of illogical initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis. A meta-analysis of clinical and radiographic remission. Ann Rheum Dis. 2010 Jul,69(7): 1298-304.
  12. Scott D; Kingsley G. Tumor Necrosis factor Inhibitors for Rheumatoid Arthritis. The new England Journal of Medicine 2006; 355:704.
  13. Maini R; Breedveld F; Furst D; Kalden J; Weisman M; Smolen J; et. al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999 Dec 4;354(9194):1932-9.
  14. Zintzaras E; Dahabreh J; Giannouli S; Voulgarelis M; Moutsopoulos HM; Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther. 2008 Nov;30(11):1939-55.
  15. Bombardieri S, Tzioufas AG, McKenna F, Ozer U, Kupper H. Adalimumab (Humira) is effective in treating patients with rheumatoid arthritis who previously failed etanercept and/or infliximab in real-life settings. Arthritis Rheum. 2005;52:S144.
  16. Van der Heijde D, Klareskog L, Landewé R, Bruyn GA, Cantagrel A, Durez P, et. al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007 Dec;56(12):3928-39.
  17. Scrivo R, Armignacco O. Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data. International Journal of Rheumatic Diseases 2014; 17: 716–724.
  18. Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapiestargeting TNF. Ann Rheum Dis 2003;62(Suppl II): ii37–ii42.
  19. Patkar N, Tengb GG, Curtisa J, Saaga K. Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr Opin Rheumatol 2008, 20:320–6.
  20. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, et. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 2010; 49:2217–2219.
  21. Alexis J; Guilarte R, Pautas y guías para el diagnóstico y el tratamiento de tuberculosis en pacientes con artritis reumatoide a ser tratados con agentes biológicos (anti-TNF). ISSN: 2443-4388 N° 36, Año 2015.
  22. Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum. 2008 Apr;58(4):947-52.
  23. ODPM 2001 “Allocation of housing capital resources” (Londres: Office of the Deputy Prime Minister).
  24. Paluch-Oleś J, Magryś A, Kozioł-Montewka M, Koszarny A, Majdan M. Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-αagents. Arch Med Sci 2013; 9, 1: 112-117
  25. Bernala J, Mariano A, Vega J, García R, Begazo A, Vela P. Primoinfección tuberculosa en pacientes con anti TNF alfa y cribado inicial negativo. Reumatol Clin. 2016; 12:81-4 - Vol. 12 Núm.2
  26. Guilarte A, Ponte H, Valera J, García J, Levy G, España M, et. al. Despistaje, diagnóstico y tratamiento de la tuberculosis en pacientes con indicación de terapias biológicas.
  27. Nordgaard-Lassen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, et. al.Guidelines for screening, prophylaxis and critical information prior to initiating anti-tnf-alpha treatment. Dan Med J. 2012 Jul;59(7):C4480.
  28. Barragán J. Tratamiento con terapia biológica en enfermedades reumatológicas y su relación con tuberculosis Med Int Mex 2011;27(1):52-57.
  29. Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent terculosis infection. CMAJ. 2003 Apr 29; 168(9): 1153–1156.
  30. Keane, J. y Bresnihan, B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic disease: diagnostic y therapeutic strategies. Curr Opin Rheumatol. 2008 Jul;20(4):443-9.
  31. Stagg H; Zenner D; Harris R; Muñoz L; Lipman; Abubakar I. Treatment of Latent Tuberculosis Infection A Network Meta-analysis Intern Med. 2014; 161:419-428. 12 August 2014.
  32. Patkar N, Tengb GG, Curtisa J, Saaga K. Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr Opin Rheumatol 2008, 20:320–6.
  33. Gómez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007 Jun 15;57(5):756-61.
  34. Carmona, L; Gómez-Reino J, BIOBADASER Group. Survival of TNF antagonists in spondyloarthritis is better that in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006; 8(3): R72.
  35. Jung SM, Ju JH, Park MS, Kwok SK, Park KS, Kim HY, et. al. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden. International Journal of Rheumatic Diseases. Int J Rheum Dis. 2015 Mar;18(3):323-30.
  36. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et. al.Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009 Jul;60(7):1884-94.
  37. Pérez-Barbosa L, Esquivel-Valerio JA, Arana-Guajardo AC, Vega-Morales D, Riega-Torres J, Garza-Elizondo MA. Increased detection of latent tuberculosis by tuberculin skin test and booster phenomenon in early rheumatoid arthritis patients. Rheumatol Int (2015) 35:1555–1559.
  38. Ai JW, Zhang S, Ruan QL, Yu YQ, Zhang BY, Liu QH, Zhang WH. The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies. J
  39. Rheumatol. 2015 Dec;42(12):2229-37.
  40. Winthrop K, Baxter R, Liu L, Varley C, Curtis J, Baddley J, et. Mycobacterial diseases and antitumour necrosis factor therapy in USA. ARD Online First, published on April 20, 2012 as 10.1136/annrheumdis-2011-200690.
  41. Weyand CM, Fulbright JW, Goronzy JJ (2003) Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerontol38:833–841
  42. Lee KH, Jung SY, Ha YJ, Lee SK, Park YB (2012) Tuberculin reaction is not attenuated in patients with rheumatoid arthritis living in a region with intermediate burden of tuberculosis. Rheumatol Int 32:1421–1424
  43. Catagay T, Aydin M, Sunmez S, Catagay P, Gulbaran Z, Gul A, et (2010) Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int 30:1459-1463
  44. Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Lagana B, Gatta L et al (2014) Higher risk of tuberculosis reactivation when anti- TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med 8:1–8.doi:10.3109/07853890.2014.941919
  45. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter activesurveillance report. Arthritis Rheum 48:2122–212
  46. Carmona L, Gómez-Reino JJ, Rodíguez-Velarde V, Montero D, Pascual-Gómez E, Mola EM et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766–1772.
  47. Curtis J, Jain A, Asklin S.L, Carmona L, Dixon W, Finchk A. A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis. Semin Arthritis Rheum, 40 (2010), pp. 2-14.
  48. Curtis J.R, Singh J.A. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther, 33 (2011), pp. 679-707